vs

Side-by-side financial comparison of FIRST US BANCSHARES, INC. (FUSB) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $10.4M, roughly 1.9× FIRST US BANCSHARES, INC.). FIRST US BANCSHARES, INC. runs the higher net margin — 20.4% vs -177.4%, a 197.8% gap on every dollar of revenue. On growth, FIRST US BANCSHARES, INC. posted the faster year-over-year revenue change (7.1% vs -11.5%). FIRST US BANCSHARES, INC. produced more free cash flow last quarter ($9.1M vs $-23.1M). Over the past eight quarters, FIRST US BANCSHARES, INC.'s revenue compounded faster (2.6% CAGR vs -12.2%).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FUSB vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.9× larger
LAB
$19.6M
$10.4M
FUSB
Growing faster (revenue YoY)
FUSB
FUSB
+18.5% gap
FUSB
7.1%
-11.5%
LAB
Higher net margin
FUSB
FUSB
197.8% more per $
FUSB
20.4%
-177.4%
LAB
More free cash flow
FUSB
FUSB
$32.2M more FCF
FUSB
$9.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FUSB
FUSB
Annualised
FUSB
2.6%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FUSB
FUSB
LAB
LAB
Revenue
$10.4M
$19.6M
Net Profit
$2.1M
$-34.7M
Gross Margin
48.5%
Operating Margin
28.1%
-168.5%
Net Margin
20.4%
-177.4%
Revenue YoY
7.1%
-11.5%
Net Profit YoY
24.2%
-28.8%
EPS (diluted)
$0.36
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FUSB
FUSB
LAB
LAB
Q4 25
$10.4M
Q3 25
$10.5M
$19.6M
Q2 25
$10.3M
$21.8M
Q1 25
$9.8M
$40.8M
Q4 24
$9.7M
Q3 24
$10.1M
$22.1M
Q2 24
$10.0M
$22.5M
Q1 24
$9.9M
$45.5M
Net Profit
FUSB
FUSB
LAB
LAB
Q4 25
$2.1M
Q3 25
$1.9M
$-34.7M
Q2 25
$155.0K
$-33.5M
Q1 25
$1.8M
$-26.0M
Q4 24
$1.7M
Q3 24
$2.2M
$-26.9M
Q2 24
$2.1M
$-45.7M
Q1 24
$2.1M
$-32.2M
Gross Margin
FUSB
FUSB
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
FUSB
FUSB
LAB
LAB
Q4 25
28.1%
Q3 25
23.9%
-168.5%
Q2 25
1.6%
-118.1%
Q1 25
23.8%
-80.8%
Q4 24
23.8%
Q3 24
29.2%
-120.9%
Q2 24
27.4%
-134.5%
Q1 24
27.8%
-132.2%
Net Margin
FUSB
FUSB
LAB
LAB
Q4 25
20.4%
Q3 25
18.4%
-177.4%
Q2 25
1.5%
-153.7%
Q1 25
18.1%
-63.8%
Q4 24
17.6%
Q3 24
22.0%
-122.0%
Q2 24
21.2%
-203.3%
Q1 24
21.3%
-70.6%
EPS (diluted)
FUSB
FUSB
LAB
LAB
Q4 25
$0.36
Q3 25
$0.32
$-0.09
Q2 25
$0.03
$-0.09
Q1 25
$0.29
$-0.07
Q4 24
$0.29
Q3 24
$0.36
$-0.07
Q2 24
$0.34
$-0.12
Q1 24
$0.34
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FUSB
FUSB
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$73.5M
$129.4M
Total DebtLower is stronger
$10.9M
Stockholders' EquityBook value
$105.6M
$399.7M
Total Assets
$1.2B
$539.6M
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FUSB
FUSB
LAB
LAB
Q4 25
$73.5M
Q3 25
$54.7M
$129.4M
Q2 25
$54.0M
$158.6M
Q1 25
$56.0M
$150.9M
Q4 24
$47.2M
Q3 24
$82.3M
$210.6M
Q2 24
$58.2M
$269.8M
Q1 24
$60.2M
$287.1M
Total Debt
FUSB
FUSB
LAB
LAB
Q4 25
$10.9M
Q3 25
$10.9M
Q2 25
$10.9M
Q1 25
$10.9M
Q4 24
$10.9M
Q3 24
$10.9M
$55.2M
Q2 24
$10.8M
$55.1M
Q1 24
$10.8M
$55.0M
Stockholders' Equity
FUSB
FUSB
LAB
LAB
Q4 25
$105.6M
Q3 25
$104.2M
$399.7M
Q2 25
$101.9M
$424.5M
Q1 25
$101.2M
$454.6M
Q4 24
$98.6M
Q3 24
$98.5M
$489.3M
Q2 24
$93.8M
$510.3M
Q1 24
$92.3M
$577.3M
Total Assets
FUSB
FUSB
LAB
LAB
Q4 25
$1.2B
Q3 25
$1.1B
$539.6M
Q2 25
$1.1B
$557.0M
Q1 25
$1.1B
$579.6M
Q4 24
$1.1B
Q3 24
$1.1B
$681.5M
Q2 24
$1.1B
$708.7M
Q1 24
$1.1B
$777.7M
Debt / Equity
FUSB
FUSB
LAB
LAB
Q4 25
0.10×
Q3 25
0.10×
Q2 25
0.11×
Q1 25
0.11×
Q4 24
0.11×
Q3 24
0.11×
0.11×
Q2 24
0.12×
0.11×
Q1 24
0.12×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FUSB
FUSB
LAB
LAB
Operating Cash FlowLast quarter
$12.3M
$-22.2M
Free Cash FlowOCF − Capex
$9.1M
$-23.1M
FCF MarginFCF / Revenue
87.2%
-118.1%
Capex IntensityCapex / Revenue
31.1%
4.5%
Cash ConversionOCF / Net Profit
5.79×
TTM Free Cash FlowTrailing 4 quarters
$16.0M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FUSB
FUSB
LAB
LAB
Q4 25
$12.3M
Q3 25
$4.2M
$-22.2M
Q2 25
$3.9M
$-20.7M
Q1 25
$1.8M
$-30.3M
Q4 24
$7.8M
Q3 24
$1.9M
$-27.9M
Q2 24
$2.5M
$-39.0M
Q1 24
$825.0K
$-62.5M
Free Cash Flow
FUSB
FUSB
LAB
LAB
Q4 25
$9.1M
Q3 25
$3.6M
$-23.1M
Q2 25
$1.6M
$-22.6M
Q1 25
$1.7M
$-35.3M
Q4 24
$5.7M
Q3 24
$1.3M
$-30.1M
Q2 24
$2.3M
$-41.0M
Q1 24
$-142.0K
$-63.3M
FCF Margin
FUSB
FUSB
LAB
LAB
Q4 25
87.2%
Q3 25
34.2%
-118.1%
Q2 25
16.0%
-103.6%
Q1 25
17.2%
-86.6%
Q4 24
58.2%
Q3 24
12.7%
-136.4%
Q2 24
23.5%
-182.2%
Q1 24
-1.4%
-138.9%
Capex Intensity
FUSB
FUSB
LAB
LAB
Q4 25
31.1%
Q3 25
5.9%
4.5%
Q2 25
21.8%
8.7%
Q1 25
0.7%
12.4%
Q4 24
21.6%
Q3 24
6.6%
10.2%
Q2 24
2.0%
8.6%
Q1 24
9.8%
1.7%
Cash Conversion
FUSB
FUSB
LAB
LAB
Q4 25
5.79×
Q3 25
2.18×
Q2 25
25.16×
Q1 25
0.99×
Q4 24
4.53×
Q3 24
0.87×
Q2 24
1.20×
Q1 24
0.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FUSB
FUSB

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons